BMS-Hengrui Pact Highlights China’s Rising Role in Drug Development

A new global licensing and research agreement between Bristol Myers Squibb (BMS) and Hengrui Pharma highlights the trend of US pharma companies using China-based firms’ early clinical development infrastructure to accelerate proof-of-concept decisions.1 The agreement includes $600 million upfront and could reach $15.2 billion in total value, spanning 13 early-stage programs across oncology, hematology, and immunology.

“Tapping capabilities across geographies could cut the time to early clinical insights and support informed decisions,” Robert Plenge, MD, PhD, research chief, Bristol Myers Squibb, stated in a press release,1 Plenge points less to a single asset transaction than to a broader portfolio strategy built around trial-start speed, earlier human data generation, and regional division of development responsibilities.

What Does the Agreement Include?

The transaction gives BMS exclusive rights to four Hengrui oncology and hematology assets outside the mainland of China and establishes joint discovery and development work on five additional candidates.1 The structure also includes rights granted to Hengrui for four BMS immunology assets in China, with Hengrui taking responsibility for early development in humans.

Rather than relying only on external in-licensing, the arrangement also places internal BMS candidates into a regional development model designed to reach clinical proof of concept more quickly.1 These structures can affect clinical supply planning, analytical transfer, comparability strategy, and regulatory sequencing across regions.

Why is China-based Development Becoming so Prevalent?

This deal is a part of a broader industry movement toward China for early clinical work. The interval from early discovery to clinical trial filing is 50% to 70% faster in China than in the rest of the world.1,2 That speed differential has implications for portfolio governance because earlier first-in-human data can shape whether sponsors expand process development, scale-up activities, and later-stage manufacturing investments.

Working with a China-based firm may offer accelerated enrollment and startup timelines but also earlier feedback on formulation suitability, biomarker strategy, and dose-selection assumptions.2 Those advantages, however, do not remove the need for careful global development planning, particularly where data packages will later support multinational regulatory interactions.

How Does this Deal Compare With Other Hengrui Partnerships?

The BMS-Hengrui alliance is different from previous deals Hengrui made with US-based firms because it includes assets from both parties rather than a simpler one-way license.1,3 A bidirectional arrangement may create a more integrated development network, potentially involving shared decisions about candidate selection, early clinical execution, and future commercialization options.

GSK entered a separate Hengrui transaction in 2025 involving one licensed candidate and options on 11 other programs, with Hengrui positioned to advance those assets through phase 1.3 GSK paid $500 million upfront for the collaboration and did not include exclusive rights to any products in their drug portfolio for Hengrui. These agreements suggest sustained interest among large drug developers in accessing China-originated assets and development capabilities.

What Are the Operational limits of this Deal?

No asset-level efficacy, safety, or clinical trial design data were disclosed, limiting assessment of scientific risk, manufacturability, and modality-specific development complexity.1 The practical value of the agreement will depend on whether faster, early studies translate into decision-quality data that can support later global development.

At the moment, the transaction is best understood as large pharma companies pairing external pipeline access with regional early-development execution in an effort to shorten the path to proof of concept.

References

1. Bristol Myers Squibb. Bristol Myers Squibb and Hengrui Pharma announce strategic agreements to advance innovative medicines across oncology, hematology, and immunology. Press release. May 12, 2026. https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-and-Hengrui-Pharma-Announce-Strategic-Agreements-to-Advance-Innovative-Medicines-Across-Oncology-Hematology-and-Immunology-2026-EbQpaI6Zdc/default.aspx
2. McKinsey & Company. The emerging epicenter: Asia’s role in biopharma’s future. Accessed May 12, 2026. https://www.mckinsey.com/industries/life-sciences/our-insights/the-emerging-epicenter-asias-role-in-biopharmas-future
3. Hengrui Pharma Co. Ltd.; GlaxoSmithKline plc. Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across respiratory, immunology & inflammation and oncology. Press release. July 27, 2025.https://www.prnewswire.com/news-releases/hengrui-pharma-and-gsk-enter-agreements-to-develop-up-to-12-innovative-medicines-across-respiratory-immunology--inflammation-and-oncology-302514566.html